CARMIEL, Israel, May 14, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), today announced that Moshe Manor, the Company's President and Chief Executive Officer, will present a corporate overview at the 2015 UBS Global Healthcare Conference and the Jefferies 2015 Global Healthcare Conference. Details regarding the presentations are as follows:
|2015 UBS Global Healthcare Conference|
|Wednesday, May 20, 2015 at 10:30 AM ET|
|The Sheraton New York Times Square Hotel, New York, NY|
|Jefferies 2015 Global Healthcare Conference|
|Thursday, June 4, 2015 at 1:00PM PM ET|
|The Grand Hyatt Hotel, New York, NY|
A live webcast of each presentation will be available at www.protalix.com on the event calendar page and a replay of each conference will be archived and available after the respective conference.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012, by Israel's Ministry of Health in September 2012, by the Brazilian National Health Surveillance Agency (ANVISA) in March 2013, by the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) in April 2013, by the Australian Therapeutic Goods Administration (TGA) in May 2014 and by the regulatory authorities of other countries. Marketing applications for taliglucerase alfa have been filed in additional territories as well. Protalix has partnered with Pfizer Inc. for the worldwide development and commercialization of taliglucerase alfa, excluding Israel and Brazil, where Protalix retains full rights. Protalix's development pipeline includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-112, an orally-delivered glucocerebrosidase enzyme that is produced and encapsulated within carrot cells, also for the treatment of Gaucher disease; PRX-106, an orally-delivered anti-inflammatory treatment; PRX-110 for the treatment of Cystic Fibrosis; and others.
CONTACT: Investor Contact Marcy Nanus The Trout Group, LLC 646-378-2927 firstname.lastname@example.orgSource:Protalix BioTherapeutics, Inc.